IRVINE, Calif.--(BUSINESS WIRE)--BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today reported its financial results for its first quarter ended March 31, 2017.
2017 First Quarter highlights with comparisons to 2016 First Quarter include:
Worldwide revenue of $10.9 million, a decline of 1%, driven by a
13% decline in international sales, substantially offset by a 7%
increase in U.S. revenue
- 25% increase in U.S. Waterlase revenue and a 43% increase in U.S. Waterlase placements as propelled by the launch of Waterlase Express™
- Quarterly average selling price of flagship Waterlase® iPlus continued to increase
- Worldwide services revenue increased 9%
- Operating loss decreased by 6%
- Gross margin of 36%, increased more than 325 basis points, due to improved pricing and geographic sales mix
- Appointed financial executive Mark Nelson as Senior Vice President and Chief Financial Officer
- Recruited veteran of medical device sales James Surek as Vice President of Sales for the Americas
- Successfully completed $10.5 million private placement in April 2017
President and CEO Harold Flynn, Jr. said, “Our revenues for the first quarter were essentially flat year over year, but we continued to see signs of progress. In the U.S., Waterlase placements were up 43%, which helped drive a 25% increase in Waterlase revenue in our largest single market. While still in the initial stages of ramping our launch, clinician reaction to our new fifth generation Waterlase Express technology, especially its elegantly simple user interface, educational support animations and its ease of use overall, has been very positive and encouraging. Operationally, our gross margins improved year over year, and we cut our operating loss by 6%. We also strengthened our senior management team with two key hires during the quarter, and in early April completed a $10.5 million private placement that provides funds to push forward on our strategic path toward our vision of fundamentally changing dentistry with laser technology.
“Looking forward, we are still in the early stages of transformation as a company, operating in a global dental industry also undergoing significant change, structurally, operationally, and technologically. While we may continue to experience uneven revenue growth quarter to quarter, I am confident we are developing the right solutions to address the challenges in this new emerging world of dentistry. Our technologies bring the frontier of treatment into the general practice as clinicians offer more comprehensive treatment plans, providing them minimally invasive treatments that will make them better dentists and produce better outcomes for patients. Even though we now have laser systems for every clinic and dentist around the world, our long-term challenge continues to be to educate and execute, to break the long-standing status quo and enable laser dentistry to become the new global standard of care that helps build sustainable and thriving practices. I believe in and am committed to a future with market penetration of all-tissue lasers over five times, and utilization well over 10 times where they are today. Although this is an ongoing process, we are encouraged by the progress we have made thus far.”
2017 First Quarter Financial Results
Net Revenue. Net revenue for the first quarter of 2017 was $10.9 million, as compared to net revenue of $11.0 million for the first quarter of 2016. The quarter-over-quarter decrease of 1% was driven by decreases in international Waterlase sales, worldwide Epic sales, worldwide imaging sales and domestic consumables and other revenue, substantially offset by increased domestic Waterlase sales and domestic services revenue. License fees and royalty revenue remained flat quarter-over-quarter.
Gross Profit. Gross profit typically fluctuates with product and regional mix, selling prices, product costs and revenue levels. Gross profit for the first quarter of 2017 was 36%, as compared to 33% in the first quarter of 2016, an increase of over 325 basis points. Improvements reflect an increase in net revenue and a larger concentration of domestic laser sales, specifically the Waterlase iPlus, which typically have higher product margins than our international sales due to higher pricing.
Operating Expenses. Total operating expenses in the first quarter of 2017 and 2016 were consistent at $8.0 million. Within operating expenses, sales and marketing expenses increased by $380,000, primarily due to higher convention related and advertising expenses, and general and administrative expenses increased by $149,000, primarily due to increased patent fees. These increases were more than offset by a $457,000 decrease in engineering and development expenses, primarily due to a decrease in operating supplies and payroll and consulting related expenses.
Net Loss. Net loss for the first quarter of 2017 was $4.1 million, or a $0.06 loss per share, compared to a net loss of $4.3 million, or a $0.07 loss per share, for the first quarter of 2016. The decrease in net loss was primarily attributed to a $445,000 reduction in cost of revenue resulting in a $309,000 increase in gross profit.
After adding back the first quarter’s net interest income of $9,000, removing the income tax provision of $40,000, removing the non-cash depreciation and amortization expenses of $290,000 and removing the non-cash stock-based compensation of $379,000, the non-GAAP net loss for the first quarter of 2017 totaled $3.4 million, or a loss of $0.05 per share, compared with a non-GAAP net loss of $3.2 million, or a loss of $0.06 per share, during the first quarter of 2016.
Liquidity and Capital Resources
As of March 31, 2017, BIOLASE had approximately $12.2 million in working capital. Cash and restricted cash equivalents at the end of the first quarter of 2017 were $3.8 million, as compared to $9.2 million on December 31, 2016. Net accounts receivable totaled $9.2 million at March 31, 2017, as compared to $9.8 million at December 31, 2016.
Senior Vice President and CFO Mark Nelson said, “We are pleased to have executed our private placement earlier in the month of April, and appreciate the additional runway this financing will provide for the successful expansion of our new Waterlase Express offering.” Mr. Nelson continued, “We are also encouraged that the early traction we saw in first quarter gross and operating margins will continue to benefit from anticipated growth in sales of our new Express product, ongoing improvements in pricing, and the continued expansion of our service and consumables revenue streams.”
As previously announced, BIOLASE will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the first quarter of 2017, and to answer questions. To listen to the conference call live via telephone, dial 1-877-407-4019 from the U.S. or, for international callers, dial 1-201-689-8337, approximately 10 minutes before the start time. To listen to the conference call live via the Internet, visit the Investors section of the BIOLASE website at www.biolase.com.
About BIOLASE, Inc.
BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 210 patented and 90 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold approximately 34,200 laser systems to date in over 90 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer markets.
For updates and information on Waterlase® iPlus™ and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, LinkedIn at www.linkedin.com/company/biolase, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.
BIOLASE® and Waterlase® are registered trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding expected effects of the April 2017 financing and anticipated growth. Forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described, from time-to-time, in the “Risk Factors” section of BIOLASE’s annual and quarterly reports filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.
|CONSOLIDATED STATEMENTS OF OPERATIONS|
|(in thousands, except per share data)|
|Three Months Ended|
|Products and services revenue||$||10,842||$||10,979|
|License fees and royalty revenue||32||31|
|Cost of revenue||6,921||7,366|
|Sales and marketing||4,184||3,804|
|General and administrative||2,416||2,267|
|Engineering and development||1,429||1,886|
|Total operating expenses||8,029||7,957|
|Loss from operations||(4,076||)||(4,313||)|
|(Loss) gain on foreign currency transactions||(1||)||71|
|Interest income, net||9||17|
|Non-operating income, net||8||88|
|Loss before income tax provision||(4,068||)||(4,225||)|
|Income tax provision||40||40|
|Net loss per share:|
|Shares used in the calculation of net loss per share:|
|CONSOLIDATED BALANCE SHEETS|
|(unaudited, in thousands except per share data)|
|March 31, 2017||December 31, 2016|
|Cash and cash equivalents||$||3,576||$||8,924|
|Restricted cash equivalent||251||251|
|Accounts receivable, less allowance of $1,219 in 2017 and $1,209 in 2016||9,220||9,784|
|Prepaid expenses and other current assets||1,576||1,505|
|Total current assets||29,316||33,987|
|Property, plant and equipment, net||4,465||4,478|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Deferred revenue, current portion||2,666||3,010|
|Total current liabilities||17,106||18,014|
|Deferred income taxes, net||813||798|
|Deferred revenue, long-term||20||23|
|Warranty accrual, long-term||487||773|
|Other liabilities, long-term||248||268|
|Preferred stock, par value $0.001||—||—|
|Common stock, par value $0.001||68||68|
|Additional paid-in capital||201,577||201,198|
|Accumulated other comprehensive loss||(846||)||(876||)|
|Total stockholders’ equity||18,366||22,065|
|Total liabilities and stockholders’ equity||$||37,040||$||41,941|
|CONSOLIDATED STATEMENTS OF CASH FLOWS|
|(unaudited, in thousands)|
|Three Months Ended March 31,|
|Cash Flows from Operating Activities:|
Adjustments to reconcile net loss to net cash and
cash equivalents used in operating activities:
|Depreciation and amortization||290||212|
|Provision (recovery) for bad debts, net||10||(15||)|
|Provision for inventory excess and obsolescence||225||—|
|Deferred income taxes||15||15|
|Earned interest income, net||(9||)||(16||)|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other current assets||146||(31||)|
|Accounts payable and accrued liabilities||(885||)||(155||)|
|Net cash and cash equivalents used in operating activities||(5,122||)||(4,772||)|
|Cash Flows from Investing Activities:|
|Purchases of property, plant, and equipment||(208||)||(343||)|
|Net cash and cash equivalents used in investing activities||(208||)||(343||)|
|Cash Flows from Financing Activities:|
|Principal payments under capital lease obligation||(43||)||(43||)|
|Net cash and cash equivalents used in financing activities||(43||)||(43||)|
|Effect of exchange rate changes||25||86|
|Decrease in cash and cash equivalents||(5,348||)||(5,072||)|
|Cash and cash equivalents, beginning of period||8,924||11,699|
|Cash and cash equivalents, end of period||$||3,576||$||6,627|
|Supplemental cash flow disclosure - Cash Paid:|
|Income taxes paid||$||7||$||33|
|Supplemental cash flow disclosure - Non-cash:|
|Accrued capital expenditures and tenant improvement allowance||$||174||$||70|
In addition to the financial information prepared in conformity with generally accepted accounting principles in the United States (“GAAP”), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company’s ongoing core operating performance than their GAAP equivalents.
Non-GAAP net loss is defined as net loss before interest, taxes, depreciation and amortization, and stock-based compensation. Management uses non-GAAP net loss in its evaluation of the Company’s core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.
|Reconciliation of GAAP Net Loss to Non-GAAP Net Loss|
|(unaudited, in thousands, except per share data)|
|Three Months Ended|
|GAAP net loss||$||(4,108||)||$||(4,265||)|
|Interest income, net||(9||)||(17||)|
|Income tax provision||40||40|
|Depreciation and amortization expense||290||212|
|Non-GAAP net loss||$||(3,408||)||$||(3,196||)|
|GAAP net loss per share, basic and diluted||$||(0.06||)||$||(0.07||)|
|Interest income, net||—||—|
|Income tax provision||—||—|
|Depreciation and amortization expense||—||—|
|Non-GAAP net loss per share, basic and diluted||$||(0.05||)||$||(0.06||)|